Establishment of a novel cell line for producing replication-competent adenovirus-free adenoviruses.
Adenoviruses
Cell line
E1
L132
Replication-competent adenovirus
Journal
BMC biotechnology
ISSN: 1472-6750
Titre abrégé: BMC Biotechnol
Pays: England
ID NLM: 101088663
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
11
07
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Adenoviruses are commonly utilized as viral vectors for gene therapy, genetic vaccines, and recombinant protein expression. To generate replication-defective adenoviruses, E1-complementing cell lines such as HEK293A are utilized; however, limitations remain. Repeated passage of E1-deleted virus in HEK293A cells increases the occurrence of replication-competent adenoviruses (RCAs). In the present study, we developed a novel cell line originating from human primary cells. L132 cells were transduced two times with E1-encoded retrovirus and three times with E1A-encoded retrovirus. Finally, we selected the most productive L132 cell line for generation of RCA-free adenovirus, GT541. GT541 can serve as an alternative cell line to HEK293A and other adenovirus-producing cells.
Identifiants
pubmed: 39334326
doi: 10.1186/s12896-024-00894-x
pii: 10.1186/s12896-024-00894-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Informations de copyright
© 2024. The Author(s).
Références
Sallard E, Zhang W, Aydin M, Schröer K, Ehrhardt A. The adenovirus vector platform: novel insights into rational vector design and lessons learned from the COVID-19 vaccine. Viruses. 2023;15(1):204.
doi: 10.3390/v15010204
pubmed: 36680244
pmcid: 9862123
Von Seggern DJ, Nemerow GR. Adenoviral vectors for protein expression. In: Gene expression systems. 1999. p. 111–156.
Ko HJ, Kim YJ. Antigen delivery systems: past, present, and future. Biomol Ther (Seoul). 2023;31(4):370–87.
doi: 10.4062/biomolther.2023.006
pubmed: 37072288
Kirschweger G. Crucell: Biopharmaceuticals-As Human as They Get. Mol Ther. 2003;7(1):5–6.
doi: 10.1016/S1525-0016(02)00045-X
pubmed: 12613447
Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29(2):160–79.
doi: 10.1089/hum.2017.218
pubmed: 29338444
Wei Q, Fan J, Liao J, Zou Y, Song D, Liu J, Cui J, Liu F, Ma C, Hu X, et al. Engineering the Rapid Adenovirus Production and Amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses. Cell Physiol Biochem. 2017;41(6):2383–98.
doi: 10.1159/000475909
pubmed: 28463838
Louis N, Evelegh C, Graham FL. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology. 1997;233(2):423–9.
doi: 10.1006/viro.1997.8597
pubmed: 9217065
Murakami P, Pungor E, Files J, Do L, van Rijnsoever R, Vogels R, Bout A, McCaman M. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Hum Gene Ther. 2002;13(8):909–20.
doi: 10.1089/10430340252939023
pubmed: 12031124
Kovesdi I, Hedley SJ. Adenoviral producer cells. Viruses. 2010;2(8):1681–703.
doi: 10.3390/v2081681
pubmed: 21994701
pmcid: 3185730
Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel). 2006;123:165–76 discussion 183–197.
pubmed: 16566444
White E. Regulation of apoptosis by adenovirus E1A and E1B Oncogenes. Semin Virol. 1998;8(6):505–13.
doi: 10.1006/smvy.1998.0155
Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol. 1997;71(3):1739–46.
doi: 10.1128/jvi.71.3.1739-1746.1997
pubmed: 9032302
pmcid: 191242
Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev. 1996;10(4):461–77.
doi: 10.1101/gad.10.4.461
pubmed: 8600029
Zapata-Cardona MI, Flórez-Álvarez L, Gómez-Gallego DM, Moncada-Díaz MJ, Hernandez JC, Díaz F, Rugeles MT, Aguilar-Jiménez W, Zapata W. Comparison among plaque assay, tissue culture infectious dose (TCID(50)) and real-time RT-PCR for SARS-CoV-2 variants quantification. Iran J Microbiol. 2022;14(3):291–9.
pubmed: 37124861
pmcid: 10132340
Lei C, Jian Y, Hu J, Sun X: On the calculation of TCID50 for quantitation of virus infectivity. Virol Sin . 2021;36(1):141–44.
Zhao H, Chen M, Pettersson U. A new look at adenovirus splicing. Virology. 2014;456–457:329–41.
doi: 10.1016/j.virol.2014.04.006
pubmed: 24889252
Yallop C, Crowley J, Cote J, Hegmans‐Brouwer K, Lagerwerf F, Gagne R, Martin J, Oosterhuis N, Opstelten D, Bout A. In book: Modern Biopharmaceuticals: Design, Development and Optimization. PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins. 2008;3:779–807.
Tan E, Chin CSH, Lim ZFS, Ng SK. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front Bioeng Biotechnol. 2021;9: 796991.
doi: 10.3389/fbioe.2021.796991
pubmed: 34966729
pmcid: 8711270
Gao GP, Engdahl RK, Wilson JM. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Hum Gene Ther. 2000;11(1):213–9.
doi: 10.1089/10430340050016283
pubmed: 10646652
Kim JS, Lee SH, Cho YS, Park K, Kim YH, Lee JH. Development of a packaging cell line for propagation of replication-deficient adenovirus vector. Exp Mol Med. 2001;33(3):145–9.
doi: 10.1038/emm.2001.25
pubmed: 11642550
Moreira AS, Silva AC, Sousa MFQ, Hagner-McWhirterc Å, Ahlénc G, Lundgren M, Coroadinha AS, Alves PM, Peixoto C, Carrondo MJT. Establishing suspension cell cultures for improved manufacturing of oncolytic adenovirus. Biotechnol J. 2020;15(4):1900411.
doi: 10.1002/biot.201900411
Imler JL, Chartier C, Dreyer D, Dieterle A, Sainte-Marie M, Faure T, Pavirani A, Mehtali M. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther. 1996;3(1):75–84.
pubmed: 8929914
Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol. 1996;70(6):4173–8.
doi: 10.1128/jvi.70.6.4173-4178.1996
pubmed: 8648763
pmcid: 190312
Farson D, Tao L, Ko D, Li Q, Brignetti D, Segawa K, Mittelstaedt D, Harding T, Yu D-C, Li Y. Development of novel E1-Complementary Cells for Adenoviral Production Free of Replication-Competent Adenovirus. Mol Ther. 2006;14(2):305–11.
doi: 10.1016/j.ymthe.2006.02.020
pubmed: 16697707
Howe JA, Pelka P, Antelman D, Wilson C, Cornell D, Hancock W, Ramachandra M, Avanzini J, Horn M, Wills K, et al. Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors. Virology. 2006;345(1):220–30.
doi: 10.1016/j.virol.2005.09.029
pubmed: 16246392
Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996;7(2):215–22.
doi: 10.1089/hum.1996.7.2-215
pubmed: 8788172
Goodwin EC, DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci U S A. 2000;97(23):12513–8.
doi: 10.1073/pnas.97.23.12513
pubmed: 11070078
pmcid: 18795
Banerjee AC, Recupero AJ, Mal A, Piotrkowski AM, Wang DM, Harter ML. The adenovirus E1A 289R and 243R proteins inhibit the phosphorylation of p300. Oncogene. 1994;9(6):1733–7.
pubmed: 8183570
Leikas AJ, Ylä-Herttuala S, Hartikainen JEK. Adenoviral gene therapy vectors in clinical use-basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety. Int J Mol Sci. 2023;24(22):16519.
doi: 10.3390/ijms242216519
pubmed: 38003709
pmcid: 10671366
Marzio G, Kerkvliet E, Bogaards JA, Koelewijn S, De Groot A, Gijsbers L, Weverling GJ, Vogels R, Havenga M, Custers J, et al. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells. Vaccine. 2007;25(12):2228–37.
doi: 10.1016/j.vaccine.2006.12.011
pubmed: 17250936
Gao M, Yngve E, Yu D, Jin C. A qPCR-Based method for quantification of RCA contaminants in oncolytic adenovirus products. Front Mol Biosci. 2022;9:883249.
Li S, Ou M, Wang G, Tang L. Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy. Appl Microbiol Biotechnol. 2016;100(19):8325–35.
doi: 10.1007/s00253-016-7806-z
pubmed: 27557721
Hidalgo P, Ip WH, Dobner T, Gonzalez RA. The biology of the adenovirus E1B 55K protein. FEBS Lett. 2019;593(24):3504–17.
doi: 10.1002/1873-3468.13694
pubmed: 31769868
von Stromberg K, Seddar L, Ip W-H, Günther T, Gornott B, Weinert S-C, Hüppner M, Bertzbach LD, Dobner T. The human adenovirus E1B–55K oncoprotein coordinates cell transformation through regulation of DNA-bound host transcription factors. Proc Natl Acad Sci. 2023;120(44): e2310770120.
doi: 10.1073/pnas.2310770120